Repositioning Candidate Details
| Candidate ID: | R0393 |
| Source ID: | DB01599 |
| Source Type: | approved; investigational |
| Compound Type: | small molecule |
| Compound Name: | Probucol |
| Synonyms: | |
| Molecular Formula: | C31H48O2S2 |
| SMILES: | CC(C)(SC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C)SC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C |
| Structure: |
|
| DrugBank Description: | A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993). |
| CAS Number: | 23288-49-5 |
| Molecular Weight: | 516.842 |
| DrugBank Indication: | Used to lower LDL and HDL cholesterol. |
| DrugBank Pharmacology: | Probucol lowers cholesterol levels by increasing LDL (low-density lipoprotein) breakdown. Additionally, probucol may inhibit cholesterol synthesis and delay cholesterol absorption. Probucol is a powerful antioxidant drug normally used to prevent vascular disease caused by the free radicals in the body. |
| DrugBank MoA: | Probucol lowers serum cholesterol by increasing the fractional rate of low-density lipoprotein (LDL) catabolism in the final metabolic pathway for cholesterol elimination from the body. This drug may also act to inhibit the initial stages of cholesterol synthesis and act to inhibit the absorption of cholesterol from the diet. Recent information suggests that probucol may inhibit the oxidation and tissue deposition of LDL cholesterol, thereby inhibiting atherogenesis. It appears to inhibits ABCA1-mediated cellular lipid efflux. |
| Targets: | ATP-binding cassette sub-family A member 1; Liver carboxylesterase 1 |
| Inclusion Criteria: |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|